Edition:
United States

Intellia Therapeutics Inc (NTLA.OQ)

NTLA.OQ on NASDAQ Stock Exchange Global Market

25.03USD
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
$25.03
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
299,053
52-wk High
$33.20
52-wk Low
$11.15

Chart for

About

Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that... (more)

Overall

Beta: --
Market Cap(Mil.): $1,059.65
Shares Outstanding(Mil.): 42.34
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Intellia Therapeutics Names John Leonard, M.D., President And CEO

* INTELLIA THERAPEUTICS NAMES JOHN LEONARD, M.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER

Dec 18 2017

BRIEF-Intellia Therapeutics prices public offering of 6.3 mln shares at $24 per share

* Intellia Therapeutics announces pricing of public offering of common stock

Nov 01 2017

BRIEF-Intellia Therapeutics announces proposed public offering of common stock

* Intellia therapeutics announces proposed public offering of common stock

Nov 01 2017

BRIEF-Intellia Therapeutics Q3 loss per share $‍0.44​

* Intellia therapeutics announces third quarter 2017 financial results

Oct 31 2017

BRIEF-Intellia Therapeutics Q3 revenue $65 mln

* Intellia Therapeutics announces third quarter 2017 financial results

Oct 31 2017

Earnings vs. Estimates